基本信息
浏览量:3
职业迁徙
个人简介
Nabeel Nabulsi, PhD
Senior Research Scientist in Radiology and Biomedical Imaging; Associate Director of PET Center, Yale PET Center; Deputy Director of PET Center Chemistry Section; Director of Regulatory Affairs and Quality Control, Yale PET Center
Research Summary
My interests in PET embrace both Chemistry and Imaging
Extensive Research Description
As a radiochemist, I find rewarding the development of facile
synthetic methodologies for the preparation of radiopharmaceuticals
which incorporate the short half-life C-11 and F-18 radionuclides that
are frequently employed for PET imaging. In particular, synthesis of
C-11 radiopharmaceuticals is very challenging in that it generally has
to be accomplished inside 60 minutes in order to possess adequate
radioactivity for PET imaging.
Improving overall binding properties of existing radioligands and the
development of new ligands comprise my imaging interest in the areas of
CNS and oncology. For CNS, I am interested in developing
radiopharmaceuticals that can be employed for early diagnosis of
Alzheimer and Parkinson diseases and which can lead to development of
better treatments. Another interesting area, FAAH (fatty acid amide
hydrolase) has emerged as a novel therapeutic target for a range of
clinical disorders. It is a membrane-bound intracellular serine
hydrolase that is responsible for AEA (Anandamide, an endogenous
cannabinoid) metabolism. Indeed, FAAH has been targeted as biomarker of
AEA which is known to modulate several physiological processes in both
peripheral and nervous system. FAAH inactivation produces proactive
subset of behavioral effects similar to that observed for direct CB1
agonists, but without inducing analogous side-effects. To date, all
evidence suggests that compounds which increase the tone of AEA, whether
blocking its transport or inhibiting its metabolism, are
therapeutically valuable for treatment. Accordingly imaging FAAH should
accelerate validation of FAAH inhibitors as therapeutic targets.
Small-molecule radiotracers not only would provide valuable research
tools for further understanding of this and other therapeutic targets,
but also allows fast validation of efficacy and selectivity of potential
drug inhibitors as well. The potential disorders which can benefit from
targeted enhancement of AEA include analgesic, anti tumor and neuroprotection.
Regarding oncology, there is a dire need for radiotracers which are
capable of early detection of pancreatic cancer. It is the second most
common gastrointestinal malignancy in the USA. Meanwhile, peptide
transporters are important drug delivery targets and growing number of
studies have been reported on regulation of their transport capacity.
Tumor cells have been shown to up-regulate the expression of the peptide
transporter type PepT1, and high levels of this transporter have been
found in variety of cancer cells, including pancreatic. Thus, increased
expression of PepT1 in the cellular membrane of cancer cells has been
investigated as a possible target for delivery of peptidomimetic
anti-cancer drugs as well as prodrugs. Bestatin, a leukotriene A4
hydrolase inhibitor, is among the peptidomimetic PepT1 substrates which
have been shown to have anticancer activity towards non-lymphocytic
leukemia as well as pancreatic adenocarcinoma. In this regard, I am
interested in developing radiotracers that are substrates of the peptide
transporter PepT1 for imaging pancreatic cancer. Alternatively,
inhibition of PepT1 activity has also been suggested as a novel
chemotherapy approach. With this in mind, radiotracers that are
substrates for PepT1 should also facilitate the development of PepT1
inhibitors.
Education & Training
Fellowship
University of Michigan Medical School (2006)
Fellowship
University of Texas M.D. Anderson Cancer Center (2001)
PhD
Louisiana State University, Chemsitry/Organic/Bioorganic (1991)
MS
Texas Tech University, Chemistry/Organic (1984)
BA
University of Texas at Arlington, Chemistry/Pre-Medicine (1980)
Senior Research Scientist in Radiology and Biomedical Imaging; Associate Director of PET Center, Yale PET Center; Deputy Director of PET Center Chemistry Section; Director of Regulatory Affairs and Quality Control, Yale PET Center
Research Summary
My interests in PET embrace both Chemistry and Imaging
Extensive Research Description
As a radiochemist, I find rewarding the development of facile
synthetic methodologies for the preparation of radiopharmaceuticals
which incorporate the short half-life C-11 and F-18 radionuclides that
are frequently employed for PET imaging. In particular, synthesis of
C-11 radiopharmaceuticals is very challenging in that it generally has
to be accomplished inside 60 minutes in order to possess adequate
radioactivity for PET imaging.
Improving overall binding properties of existing radioligands and the
development of new ligands comprise my imaging interest in the areas of
CNS and oncology. For CNS, I am interested in developing
radiopharmaceuticals that can be employed for early diagnosis of
Alzheimer and Parkinson diseases and which can lead to development of
better treatments. Another interesting area, FAAH (fatty acid amide
hydrolase) has emerged as a novel therapeutic target for a range of
clinical disorders. It is a membrane-bound intracellular serine
hydrolase that is responsible for AEA (Anandamide, an endogenous
cannabinoid) metabolism. Indeed, FAAH has been targeted as biomarker of
AEA which is known to modulate several physiological processes in both
peripheral and nervous system. FAAH inactivation produces proactive
subset of behavioral effects similar to that observed for direct CB1
agonists, but without inducing analogous side-effects. To date, all
evidence suggests that compounds which increase the tone of AEA, whether
blocking its transport or inhibiting its metabolism, are
therapeutically valuable for treatment. Accordingly imaging FAAH should
accelerate validation of FAAH inhibitors as therapeutic targets.
Small-molecule radiotracers not only would provide valuable research
tools for further understanding of this and other therapeutic targets,
but also allows fast validation of efficacy and selectivity of potential
drug inhibitors as well. The potential disorders which can benefit from
targeted enhancement of AEA include analgesic, anti tumor and neuroprotection.
Regarding oncology, there is a dire need for radiotracers which are
capable of early detection of pancreatic cancer. It is the second most
common gastrointestinal malignancy in the USA. Meanwhile, peptide
transporters are important drug delivery targets and growing number of
studies have been reported on regulation of their transport capacity.
Tumor cells have been shown to up-regulate the expression of the peptide
transporter type PepT1, and high levels of this transporter have been
found in variety of cancer cells, including pancreatic. Thus, increased
expression of PepT1 in the cellular membrane of cancer cells has been
investigated as a possible target for delivery of peptidomimetic
anti-cancer drugs as well as prodrugs. Bestatin, a leukotriene A4
hydrolase inhibitor, is among the peptidomimetic PepT1 substrates which
have been shown to have anticancer activity towards non-lymphocytic
leukemia as well as pancreatic adenocarcinoma. In this regard, I am
interested in developing radiotracers that are substrates of the peptide
transporter PepT1 for imaging pancreatic cancer. Alternatively,
inhibition of PepT1 activity has also been suggested as a novel
chemotherapy approach. With this in mind, radiotracers that are
substrates for PepT1 should also facilitate the development of PepT1
inhibitors.
Education & Training
Fellowship
University of Michigan Medical School (2006)
Fellowship
University of Texas M.D. Anderson Cancer Center (2001)
PhD
Louisiana State University, Chemsitry/Organic/Bioorganic (1991)
MS
Texas Tech University, Chemistry/Organic (1984)
BA
University of Texas at Arlington, Chemistry/Pre-Medicine (1980)
研究兴趣
论文共 383 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Jason A. Silva-Rudberg,Elaheh Salardini,Ryan S. O'Dell,Ming-Kai Chen,Jocelyn Ra, Jamie K. Georgelos,Mackenzie R. Morehouse,Kaitlyn P. Melino, Pradeep Parma,Takuya Toyonaga,Nabeel B. Nabulsi,Yiyun Huang,
Yanghong Yang,Mika Naganawa, Nora Hernadenz, Neil Nguyen,Nabeel Nabulsi,Yiyun Huang,Richard Carson,David Matuskey,Elan Louis
NEUROLOGYno. 17 (2023)
引用0浏览0引用
0
0
Biological Psychiatryno. 9 (2023): S326-S326
NeuroImage. Clinical (2023): 103457-103457
引用0浏览0WOS引用
0
0
Biological Psychiatryno. 9 (2023): S317-S318
Aarti Sawant-Basak,Laigao Chen,Peter A. Lockwood, Tracey Boyden,Angela C. Doran, James P. Mancuso,Kenneth R. Zasadny,Timothy J. McCarthy,Evan D. Morris,Richard E. Carson,Irina Esterlis,Yiyun Huang,
Biopharmaceutics & Drug Dispositionno. 1 (2023): 48-59
引用1浏览0引用
1
0
Y. Zakiniaeiz, K. McCright,A. T. Hillmer,H. Shi,N. Nabulsi,Y. Huang,D. Matuskey, G. A. Angarita,S. A. McKee,K. P. Cosgrove
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2023): 130-130
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn